Strategies for effective patient services programs
Patient adherence to therapy continues to be a challenge for pharmaceutical manufacturers. New complex patient journeys and multi-channel brand distribution models make it increasingly difficult to address patient barriers to adherence. Manufacturers continue to spend millions of dollars on patient
Spinning up the pharma traceability wheel
There are centrifugal and centripetal forces carrying along the drive toward pharma traceability today: forces that bring the pharma supply chain into a more united and cohesive effort (centripetal); forces that are sending supply chain participants in different directions (centrifugal).
The impact of Covid-19 across market access stakeholders and what it means for manufacturers
The Covid-19 pandemic continues to have a profound effect on the United States and the world. At the time of this writing, the United States has surpassed 60,000 deaths, and much of the nation is under varying degrees of lockdown.
How to successfully transition patient solutions providers
Switching patient solutions providers, also known as hub providers, is a big decision for any pharmaceutical manufacturer or life sciences organization. The transition can be a hefty lift for your team and your newly selected provider due to the amount
Innovative models to address cell- and gene-therapy (CGT) payer challenges
In the past two years, four new cell and gene therapies have entered the US market at unprecedented prices. Most recently, Zolgensma launched at a price of $2.1 million per treatment. Payers are concerned about the high cost, especially since
- Brand Marketing / Communications
- ‘Drugs to Watch’ list tags 11 about-to-be-approved therapies with blockbuster potential
- Get a flash reading of physician sentiment with COVIDPulse
- CMS should reimburse community pharmacists for at-home drug delivery, says NCPA
- UBC offers ‘intelligent mobile messaging’ in patient support programs
- 2020 Patient Support / Hub Services Report